Taking into account that IKAROS tumor suppressive capacity includes an induction of enhancers in T cells [81], the hypomethylation in SF3B1mut patients at IKAROS binding sites and the enrichment of the hypomethylation sites in weak enhancers is noticeable and requires further investigation. The gene discussed is IKZF1; the disease is neoplasm.